



GP1642

Patent Docket P1084R1-2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Paul J. Godowski et al.  Serial No.: 09/107,979  Filed: 30 June 1998  For: ErbB4 Receptor-Specific Neuregulin Related Ligands and Uses Therefor	Group Art Unit: 1642  Examiner: Nancy A. Johnson  <b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on  September 9, 1999 <i>Pamela Gavette</i> Pamela Gavette
---	---

**RESPONSE TO RESTRICTION REQUIREMENT**

Assistant Commissioner of Patents  
Washington, D.C. 20231

**RECEIVED**

SEP 16 1999

TECH CENTER 1600/2900

Sir:

This paper is being filed in response to the Office Action mailed August 11, 1999. In the Office Action, the Examiner proposed that claims 1-38 pending in the application be restricted under 35 U.S.C. 121 to the following proposed groups:

- I. Claims 1-11, drawn to a NRG3 polypeptide, classified in class 530, subclass 350;
- II. Claim 12, drawn to an antagonist, unclassified;
- III. Claim 13, drawn to an agonist, unclassified;
- IV. Claims 14-26, drawn to a polynucleotide, vectors and host cells comprising said polynucleotide and methods of recombinant expression of said polynucleotide, classified in classes 536 435, subclasses 23.1 and (252.3, 320.1 and 69.1);
- V. Claims 27-28, drawn to an antibody, classified in class 530, subclass 387.1;
- VI. Claims 29-32, drawn to an immunoadhesin, classified in class 530, subclass 87.3;
- VII. Claim 33, drawn to an antibody based detection method, classified in class 435, subclass 7.1;

- VIII. Claims 34-36, drawn to a ligand based method of detection, classified in class 435, subclass 7.1;
- IX. Claims 37-38, drawn to a gene therapy based method of treatment, classified in class 514, subclass 44.


Without acquiescing to the restriction requirement and merely to expedite prosecution of the claims, Applicants hereby elect Group VI claim(s) 29-32 with traverse.

Respectfully submitted,  
GENENTECH, INC.

Date: September 9, 1999

By: 

Deirdre L. Conley, Ph.D.  
Reg. No. 36,487



1 DNA Way  
So. San Francisco, CA 94080-4990  
Phone: (650) 225-2066  
Fax: (650) 952-9881